Medtronic upgraded to "Buy" for cardiac solutions

Medtronic is showing strong performance in its cardiac ablation solutions. This comes as the company upgrades its stock rating to "Buy." Previously, in January 2024, analyst Dragoljub Bankovic had rated Medtronic as a "Hold." He noted the company's Hugo RAS system and its good returns for shareholders. Despite economic challenges, Medtronic has shown steady growth. The company’s efforts in cardiac ablation and structural heart areas are seeing significant progress. Analysts believe this momentum could lead to even better results in the future. It is important to remember that past performance does not guarantee future success. Investors should consider their own situations before making any decisions.